What PTC Therapeutics' CFO Is Saying About Translarna's Conditional Approval

By MarketsFool.com

News that a European committee was recommending renewal of the company's Duchenne muscular dystrophy drug, Translarna, sent PTC Therapeutics (NASDAQ: PTCT) shares soaring Friday.

Continue Reading Below

Translarna is the company's only commercial-stage drug, and its sales have been growing quickly, so I reached out to PTC Therapeutics' CFO Shane Kovacs to learn more about what this news may mean to the company and its investors.

Following are questions I posed to Kovacs and his word-for-word replies. I've also included my own "between-the-lines" opinions after each reply.

Image source: Getty Images.

More From Fool.com

1. Does this news change the need for annual renewal every year?

Kovacs is quick to remind investors that conditional approval is indeed conditional. EU regulators will need to weigh in on the drug annually, so a Translarna renewal this year doesn't guarantee renewal in future years. However, it seems to me that if the EU mandates a follow-up study, then the odds favor Translarna remaining available in Europe until the release of those study results.

2. What's the timeline for the long-term study (start to stop)?

Ostensibly, PTC Therapeutics will begin recruiting patients for its trial after the official EU decision is rendered. Kovacs suggests that meetings are on deck with EU regulators regarding the specific design of the trial, and while he didn't indicate when this trial could begin, I imagine its negative impact on research and development spending will begin to be felt next year.

3. What can investors expect this trial will cost?

Can't blame a guy for trying: I gave it a shot, but Kovacs didn't bite. We don't know how many DMD patients will be enrolled in this upcoming trial, but the company's press release indicated that it has pitched a trial enrolling a number of patients similar to the number participating in its prior 228-patient ACT DMD study.

A big study like this won't be cheap, and the costs of running this trial will create additional profit headwinds. That's not good news since PTC Therapeutics is already losing money, but given that this study means Translarna can stay on the market, the news is still a net win for investors.

PTCT Research and Development Expense (TTM) data by YCharts.

4. How many people in the EU are currently receiving therapy?

No surprises here: Kovacs didn't bite on this question, either. The patient population that's addressed by Translarna is tiny, but Translarna is a high-priced medicine, so every new patient is meaningful to the top and bottom line. Previously, PTC Therapeutics estimated that about 13% of DMD patients have nonsense mutations that can be treated by Translarna, and that works out to about 2,000 patients in the United States and 5,000 patients internationally, including Europe.

5. What is the trend in new patient starts?

England is notoriously tough on pricing, so I'd have loved to be a fly on the wall during negotiations. Regardless, getting Translarna on the market in England is boosting its sales, and additional wins in markets such as Italy could offer additional tailwinds to patient starts next year.

6. What, if any, impact could this decision have on discussions with the FDA?

The big win for PTC Therapeutics would be approval in the United States. Earlier this year, competitor Sarepta Therapeutics won an accelerated approval from the U.S. Food and Drug Administration for its DMD drug, and while that approval was contentious, it suggests regulators are somewhat willing to push the envelope in order to get drugs on the market for important indications like DMD. That being said, the FDA has (so far) refused to consider PTC Therapeutics' Translarna application, and that's prompted management to file appeals in hope of getting the agency to reconsider.

Because the FDA works independently, the EU decision doesn't officially factor into PTC Therapeutics' chances. But in my view, it can't hurt.

Tying it together

PTC Therapeutics' Translarna is on pace to become a nine-figure drug in 2017, and a study in nonsense-mutation cystic fibrosis patients should produce results early next year that could significantly increase Translarna's peak sales potential. PTC Therapeutics estimates that between 3,700 and 4,200 cystic fibrosis patients in the EU could benefit from Translarna.

The company is also working with drug giant Roche Holding on therapies for another rare disease: spinal muscular atrophy, or SMA. Roche announced earlier this year that it's initiating mid-stage studies of RG7916 in SMA, and while results from trials aren't expected soon, an eventual success could help diversify PTC Therapeutics' revenue.

Overall, an official EU renewal decision on Translarna should happen in the next 3 months. Assuming it's a go, it will remove a big overhang, and potentially, it will provide investors a bit more peace of mind. However, until this company can offer up insight into a timeline for profitability, its shares are probably best left to aggressive investors.

10 stocks we like better than PTC Therapeutics When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and PTC Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of November 7, 2016

Todd Campbellhas no position in any stocks mentioned.Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned.Like this article? Follow him onTwitter, where he goes by the handle@ebcapital,to see more articles like this.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.